Kathryn Kolibaba, MD
Entospletinib (GS-9973) was well tolerated and demonstrated modest activity in patients with relapsed or refractory mantle cell lymphoma (MCL), according to the results of a phase II trial, which were presented at the 2016 ASH Annual Meeting.
“This study is ongoing to add patients in the CLL cohort, who have had previous treatment with PI3K inhibitors and Bruton tyrosine kinase inhibitors, because that definitely represents a population with unmet needs.”
Sharman JP, Kolibaba KS, Shustov AR, et al. Results of a phase 2 trial evaluating efficacy and safety of entospletinib (GS-9973) in patients with mantle cell lymphoma. Blood. 2016 128:2963.
... to read the full story